Breast Cancer Research Centre - WA

Palbociclib (Ibrance) to be added to PBS from 1 May 2019

BCRC-WA welcomes the news that Palbociclib (Ibrance) will be added to PBS for Australians with metastatic breast cancer from 1 May 2019.

Palbociclib (Ibrance) will only be available on the PBS as first line treatment for people newly diagnosed with metastatic hormone receptor positive, HER2-negative breast cancer from 1 May this year. To read more about this and how drugs are listed on the PBS visit the BCNA website.